logo-loader
VentriPoint Diagnostics Ltd.

Ventripoint Diagnostics reports progress for latest VMS +3.0 heart monitoring system

VMS is a machine, which revolutionizes the way doctors treat heart patients as it can give accurate and rapid volumetric information about all four chambers of the heart

heart in hand
Usability studies are underway at two leading Canadian hospitals to establish the effectiveness and ease of use of the VMS +3.0

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCQB:VPTDF) announced Tuesday that the development stage for its next-generation VMS +3.0 heart-monitoring system is nearing completion.

Usability studies are now underway at a pair of leading Canadian hospitals to establish the effectiveness and ease of use of VMS +3.0 and the Toronto-based company will seek regulatory approval in North America and Europe as soon as these studies are finished.

READ: VentriPoint Diagnostics eyeing big opportunity after winning first US customer for VMS plus

VMS is a machine, which revolutionizes the way doctors treat heart patients as it can give accurate and rapid volumetric information about all four chambers of the heart.

It is the only technology in the world that can perform such an analysis of all four chambers using data from a conventional 2D (two dimensional) eco-cardiogram (in other words an ultrasound test).

Ventripoint's latest system uses sensor technology, which allows for patients to move during the imaging portion of the exam, and it is compact and portable enough that it can be set up within minutes.

READ: VentriPoint Diagnostics shares nudge higher as it updates on sales efforts

“Replacing the old magnetic tracking system with our new tracking sensor technology enables patient repositioning during the examination,” said George Adams, CEO of Ventripoint. “This feature eliminates the usual restrictions on the person being scanned and will be instrumental in the ease of use by clinicians for both children and adults.”

Ventripoint is also developing a workstation version of the VMS + 3.0 software, which allows for the analysis of echocardiograms in a reading room elsewhere in the hospital. This will permit sonographers to continue to scan new patients, while studies are analyzed by cardiologists.

Ventripoint shares held steady at C$0.16 in morning trade on Tuesday.

Contact Ellen Kelleher at [email protected]

Quick facts: VentriPoint Diagnostics Ltd.

Price: $0.11

Market: TSX-V
Market Cap: $6.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Alchemist sees big market in China for medical cannabis sales

Alchemist (CSE: AMS) CEO Paul Mann and Vice President of Business Development, Asia Pacific Johnson Lee joined Steve Darling from Proactive Vancouver to discuss Alchemist looking for opportunities for cannabis in the emerging cannabis market.  Mann and Lee talk about what the industry...

2 days, 2 hours ago

2 min read